ArticleBMC pregnancy and childbirth2026
Correlation between tricuspid regurgitation and fetal cardiac structure or signs and prenatal genetic testing abnormalities in fetuses at 12
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to investigate the correlation between tricuspid regurgitation (TR) in fetuses at 12
methodsA prospective collection of dynamic four-chamber view (4CV) color Doppler ultrasound images of fetuses at 12
results(1) In this study, 1018 early gestational fetuses were included, with a 100.0% detection rate of dynamic 4CV color Doppler ultrasound images. (2) Among the 1018 fetuses, 942 were in the non-TR group, and 76 were in the TR group, yielding a TR detection rate of 7.5%. The TR group comprised 62 cases (81.6%) of mild TR, 6 cases (7.9%) of moderate TR, and 8 cases (10.5%) of severe TR. In the TR group, 12 cases (15.8%) had cardiac structural or sign abnormalities or prenatal genetic testing abnormalities, among them, there were 11 cases (14.5%) of cardiac structure or signs abnormalities, and 8 cases (10.5%) of prenatal genetic testing abnormalities.TR occurrence rate is about 6.4% in normal fetuses. The risk of cardiac structural or echocardiographic abnormalities in the TR group was 17 times higher than that in the non-TR group, and the risk of prenatal genetic testing abnormalities in the TR group was 25 times higher than that in the non-TR group. After refining the TR grade, the proportion of mild and severe abnormalities of TR in cardiac structure or signs and prenatal genetic testing abnormalities gradually increased. (3) In the early stages of pregnancy, we observed significant differences in the prevalence of hypertension and diabetes between the non-TR group and the TR group (P < 0.05), the prevalence of maternal hypertension and diabetes were 2.7% and 4.0% respectively. (4) In the early stages of pregnancy, there were no significant differences in cardiac structure or echocardiographic signs of abnormalities, nor in prenatal genetic testing abnormalities between the non-TR group and the mild TR group (P > 0.05). However, significant differences were observed in these abnormalities between the non-TR group and the following TR groups: moderate TR, severe TR, moderate + severe TR, and mild + moderate + severe TR (P < 0.05). (5) We found no significant difference between moderate TR and severe TR in cardiac structural or echocardiographic abnormalities and prenatal genetic testing abnormalities (P > 0.05). However, statistically significant differences were observed between mild TR and severe TR, as well as between mild TR and moderate + severe TR, in cardiac structural or echocardiographic abnormalities and prenatal genetic testing abnormalities (P < 0.05).
conclusionAt 12
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.